Trials / Completed
CompletedNCT01669226
First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer
A Phase II,Randomized Study of an Addition Intraperitoneal Cisplatin and Etoposide to Standard First-line Therapy in Stage IIIC and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 215 (actual)
- Sponsor
- Shanghai Gynecologic Oncology Group · Other Government
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the role of an additional intraperitoneal chemotherapy with cisplatin and etoposide in bulky advanced epithelial ovarian cancer.
Detailed description
This exploratory trial is to compare the efficacy of sequential chemotherapy, intraperitoneal chemotherapy followed by intravenous chemotherapy, versus intravenous chemotherapy alone in the first-line therapy for ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PEip (weekly) and TCiv | IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5 |
| DRUG | TCiv | IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5 |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2015-09-01
- Completion
- 2016-07-01
- First posted
- 2012-08-20
- Last updated
- 2016-12-19
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01669226. Inclusion in this directory is not an endorsement.